Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.
Eligibility Criteria
Inclusion Criteria: * Symptomatic MM in the first line in patients who are not candidates for autologous bone marrow transplantation. * Patients eligible for one of the treatments considered as standard in a patient who is not eligible for autograft, according to ESMO's European recommendations * MM with measurable disease either by the serum evaluation of the monoclonal component or by the determination of free light chains (serum or urinary). * Patient affiliated with a social insurance scheme * The patient must understand and voluntarily sign the informed consent form * Women of childbearing potential must have a serum pregnancy test (performed within 2 days before each PET scan.) * Women of childbearing potential must use an effective contraceptive method throughout the course of the study and for 30 days after the last PET. * Male patients (vasectomised or not) with a pregnant partner or a partner of childbearing potential must use a condom and a spermicide until 90 days after the